Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
21
×
biotech
life sciences
national blog main
boston blog main
boston top stories
national top stories
national
new york blog main
san francisco blog main
clinical trials
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
cancer
novartis
startups
eli lilly
merck
pfizer
astrazeneca
allergan
alzheimer's disease
amgen
What
bio
roundup
drug
fda
new
treatment
companies
medicine
acquisitions
approved
biotech
blood
ceo
company
conference
health
medicines
news
week
abbvie’s
annual
biggest
cancer
daniel
day
days
debut
disease
gilead
help
ipo
labor
latest
life
monday
moves
nash
nod
opioid
o’day
Language
unset
unknown
Current search:
abbvie
×
@xconomy.com
3 months ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
4 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
5 months ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
10 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
12 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
1 year ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
1 year ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@techcrunch.com
1 year ago
What top VCs look for in women’s fertility startups
@xconomy.com
1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@geekwire.com
1 year ago
Seattle startup Rodeo Therapeutics raises more cash for regenerative medicine treatments
@xconomy.com
1 year ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
2 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
2 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
2 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
2 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More